News und Analysen
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term.
But
Bull Market Buys: 2 Growth Stocks to Own for the Long Haul
Every good thing must come to an end -- and, eventually, the bull market we're experiencing will, too. Long-term investors must prepare for that to happen at some point.
One of the best ways to do
Bull Market Buys: 2 Growth Stocks to Own for the Long Haul
Every good thing must come to an end -- and, eventually, the bull market we're experiencing will, too. Long-term investors must prepare for that to happen at some point.
One of the best ways to do
3 No-Brainer Stocks to Buy in June
You're probably familiar with the old adage, "April showers bring May flowers." And you probably know the punchline to the question, "What do May flowers bring?" (The answer: Pilgrims.)
But what
3 Stocks to Buy for Huge Income
When it comes to dividend investing, some investors like to invest for income, and if you are searching for income, this is the video for you. Today, we will be looking at three dividend stocks that
3 Stocks to Buy for Huge Income
When it comes to dividend investing, some investors like to invest for income, and if you are searching for income, this is the video for you. Today, we will be looking at three dividend stocks that
Is Medtronic Stock a Buy?
Medtronic (NYSE: MDT) is a top healthcare company and a leading maker of medical devices. At a market cap of more than $100 billion, the business has soundly established itself in the industry. It
Is Pfizer the Best Dividend Stock for You?
The pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream. As a result, share prices have fallen and
Is Pfizer the Best Dividend Stock for You?
The pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream. As a result, share prices have fallen and
Why DraftKings Stock Cratered and May Fall Further
According to data provided by S&P Global Market Intelligence, shares of DraftKings (NASDAQ: DKNG) dropped by as much as 15.7% in trading this week after the Illinois Senate approved a new budget
Meet the 3 Largest Holdings in Harvard University's Portfolio (Hint: Nvidia Isn't 1 of Them!)
When it comes to college prestige, Ivy League schools often sit at or near the top of the pecking order. In exchange for a small fortune -- as of the 2022-2023 academic year, annual tuition and fees
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors.
*Stock prices used were the afternoon prices of May 28, 2024. The video was published on May
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors.
*Stock prices used were the afternoon prices of May 28, 2024. The video was published on May
Medtronic Stock Is a Sell, According to 1 Wall Street Analyst
One week ago, medical device maker Medtronic (NYSE: MDT) surpassed Wall Street's sales and earnings targets. Despite the earnings beat, and despite giving guidance that mostly matched analysts'
Hot IPO Viking Is a Fjord Tough Stock
May has been an adventurous month for Viking (NYSE: VIK). The world's leading operator of river cruise sailings went public at $24 on May 1. On Wednesday, it delivered its first financial update as
Beat the Dow Jones With This Cash-Gushing Dividend Stock
Since its spinoff from Pfizer in 2013, animal healthcare behemoth Zoetis (NYSE: ZTS) has seen its cash from operations nearly quintuple as a stand-alone company. Powered by a diverse array of animal
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Successful investors think about the future by focusing on what the new opportunities might be. They also pay attention to threats that could emerge that might impact the stocks they own. Sometimes
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Successful investors think about the future by focusing on what the new opportunities might be. They also pay attention to threats that could emerge that might impact the stocks they own. Sometimes
3 Dividend Stocks to Double Up on Right Now
Sometimes, misperceptions can work in investors' favor. When others think the outlook for a stock isn't so great, you can win big if that view is overly pessimistic.
Several stocks that pay
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with
Where Will Amgen Be in 3 Years?
If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (NASDAQ: AMGN), it might be worth considering a purchase. The company's development of
Where Will Amgen Be in 3 Years?
If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (NASDAQ: AMGN), it might be worth considering a purchase. The company's development of
Where Will Amgen Be in 3 Years?
If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (NASDAQ: AMGN), it might be worth considering a purchase. The company's development of